Redeye provides its initial take on Lifco’s Q2 2024 report, which came in broadly above our estimate...
Redeye updates its estimates ahead of Arise’s Q2 report, which is due on 17 July.
Ascelia proceeds with a rights issue of units to secure growth capital to be able to finalize and su...
Redeye returns following IRLAB's Q2 report and recent clinical progress.
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, men väntas förbättras i ...
Redeye leaves a short comment following Kancera's announcement from earlier this morning regarding c...
- We cut '24e-'26e ARR by 2-3% on continued macro weakness - Still awaiting a return in B2C business...
- We cut '25e-'26e EBIT by 2%... - ...and still expect no organic growth in '24e - Trading at NTM EV...
- FTX claim sold and FlowBank investment impaired - We increase adj.
Redeye provides a research update following the Q3 report recently published by Newbury.
EU-lagen CRMA (European Critical Raw Materials Act) har blivit godkänd och gäller från och med mars ...
- Q2'24 results due 22 July - 24e-'26e EBIT revised down 1.
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, som sjönk med 6% på årsb...
Redeye briefly comments on Enviro’s recent follow-up order for 500 tons of TPO from a leading Europe...
Inför Q2-rapporten räknar Analysguiden med en liknade utvecklingen som i det första kvartalet, med a...
